Global Biopharmaceutical CMO and CRO Market Size, Share, By Source (Mammalian and Non-Mammalian), By Service Type (Contract Manufacturing and Contract Research), By Product (Biologics and Biosimilars), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast

Global Biopharmaceutical CMO and CRO Market Insights Forecasts to 2035

• The Global Biopharmaceutical CMO and CRO Market Size Was Estimated at USD 39.1 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.1% from 2025 to 2035
• The Worldwide Biopharmaceutical CMO and CRO Market Size is Expected to Reach USD 74.99 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, The Global Biopharmaceutical CMO And CRO Market Size Was Worth Around USD 39.1 Billion In 2024 And Is Predicted To Grow To Around USD 74.99 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 6.1% From 2025 To 2035.    Global market expansion is fuelled by rising demand for biologics, increased cost of in-house production, growing outsourcing of R&D and manufacturing, and technological advancements.

Report Coverage

This research report categorises the biopharmaceutical CMO and CRO market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth in drivers, opportunities, and challenges influencing the biopharmaceutical CMO and CRO market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the biopharmaceutical CMO and CRO market.  

Driving Factors

The global market for the biopharmaceutical industry contract manufacturing services and contract research services is growing as pharmaceutical companies need to develop new complex and costly treatments, such as biologics and biosimilars, cell and gene therapies, and personalised medicines. The need for biopharmaceutical companies to outsource their R&D and manufacturing services is also high, mostly because they do not have the specialised facilities, equipment, or expertise to develop these complex and costly treatments. The need for contract services is also high as there is a rise in the number of biotech companies and small pharmaceutical companies, global clinical trials, single-use bioreactors and AI-enabled trial management systems.  For instance, the U.S. National Institutes of Health registry ClinicalTrials.gov contains 578109 registered clinical studies from 225 countries and territories, which demonstrates the worldwide clinical research activities in which contract research organisations (CROs)operate.

Restraining Factors

The global market for biopharmaceutical CROs and CMOs is hindered by development delays and increased operational expenses because international markets impose strict regulatory compliance requirements. The process of following various regulatory systems, including FDA requirements, demands extensive documentation and validation processes and quality control procedures. The project timeline faces disruption through approval and inspection delays, while non-compliance with regulations leads to penalties, product recalls, and damage to reputation.

Market Segmentation

The biopharmaceutical CMO and CRO market share is classified into source, service type, and product.

• The mammalian segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the source, the biopharmaceutical CMO and CRO market is divided into mammalian and non-mammalian. Among these, the mammalian segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  Mammalian systems serve as the primary method for creating complex biological products, which include monoclonal antibodies and therapeutic proteins, because these systems maintain accurate protein folding and post-translational modification processes.

• The contract research segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the service type, the biopharmaceutical CMO and CRO market is divided into contract manufacturing and contract research. Among these, the contract research segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segment leads its market because bio-pharmaceutical companies need outsourced clinical trials and regulatory support and analytical services, which enable them to decrease their development expenses and time while gaining access to particular knowledge.

• The biologics segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the product, the biopharmaceutical CMO and CRO market is divided into biologics and biosimilars. Among these, the biologics segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The rising creation and manufacturing of advanced biological treatments, which encompass monoclonal antibodies and recombinant proteins and cell and gene therapies, require special production and research facilities that CMOs and CROs provide.

 Regional Segment Analysis of the Biopharmaceutical CMO and CRO Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the biopharmaceutical CMO and CRO market over the predicted timeframe.

North America is anticipated to hold the largest share of the Biopharmaceutical CMO and CRO market because the market contains numerous major pharmaceutical and biotech companies that maintain advanced research facilities and operate under friendly regulatory systems. The U.S. market currently has many approved products that CMOs are manufacturing at their facilities. The U.S. continues to serve as the main centre for biopharmaceutical research and development because biopharmaceutical companies in 2023 dedicated approximately USD 96 billion to research efforts, which created a large portion of worldwide research funding and drove demand for CRO services.

Asia-Pacific is expected to grow at a rapid CAGR in the biopharmaceutical CMO and CRO market during the forecast period. 

The Asia-Pacific is expected to grow at a rapid CAGR because its affordable manufacturing capabilities, combined with its increased clinical trial facilities, government funding programs and its rising number of trained workers, create an appealing research and manufacturing services hub. The National Biopharma Mission (NBM) in India receives funding from the World Bank and operates under the BIRAC framework to support vaccine and bio-therapeutics and diagnostic and medical device innovations with the goal of developing India's biopharma sector into a $100 billion industry that will control 5% of the worldwide market share.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Biopharmaceutical CMO and CRO s market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lonza Group AG
• Thermo Fisher Scientific
• Catalent
• Samsung Biologics
• WuXi Biologics
• Boehringer Ingelheim
• Charles River Laboratories International
• ICON plc
• Parexel International
• IQVIA
• Syneos Health
• Medpace Holdings
• Labcorp Drug Development
• Fujifilm Diosynth Biotechnologies
• AGC Biologics

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Developments
• In March 2026, Thermo Fisher Scientific completed the acquisition of Clario Holdings Inc., a leading provider of clinical trial endpoint data and analytics solutions, for approximately USD 8.875 billion. This acquisition expands Thermo Fisher’s clinical research capabilities and enhances its contract research organization services across the drug development process.

• In January 2026, global contract research organization Evestia Clinical announced the acquisition of ICRC-Weyer GmbH, a CRO and scientific consultancy based in Germany. This acquisition aims to strengthen its comprehensive clinical research services across Europe while enhancing capabilities in biostatistics, data management, and medical writing.

• In December 2025, Samsung Biologics announced an agreement to acquire the Human Genome Sciences manufacturing site in Rockville, Maryland, from GlaxoSmithKline for USD 280 million. This facility will become its first biologics manufacturing site in the United States, supporting the expansion of its contract manufacturing operations.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the biopharmaceutical CMO and CRO s market based on the below-mentioned segments: 

Global Biopharmaceutical CMO and CRO Market, By Source

• Mammalian
• Non-Mammalian

Global Biopharmaceutical CMO and CRO Market, By Service Type

• Contract Manufacturing
• Contract Research

Global Biopharmaceutical CMO and CRO Market, By Product

• Biologics
• Biosimilars

Global Biopharmaceutical CMO and CRO Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa